Who
Benjamin Hohl
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Enliven Therapeutics.
In numbers
- Trades disclosed
- 192
- Buys
- 0
- Sells
- 47
- Bought
- $0
- Sold
- $6.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Feb 2023
- Last trade
- 19 Oct 2026
- Last filed
- 21 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 21 Oct 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $89K6,018 at $14.85 | filing |
| 19 Oct 2026filed 21 Oct 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $232K6,018 at $38.48 | filing |
| 19 Oct 2026filed 21 Oct 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,018 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $59K3,982 at $14.85 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $177K3,535 at $50.03 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $111K2,194 at $50.72 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,982 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K289 at $51.49 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,982 at $0.00 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $59K3,982 at $14.85 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $177K3,535 at $50.03 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $111K2,194 at $50.72 | filing |
| 17 Sep 2026filed 21 Sep 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $15K289 at $51.49 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $270K4,630 at $58.35 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $82K1,388 at $59.35 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $270K4,630 at $58.35 | filing |
| 17 Aug 2026filed 19 Aug 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $82K1,388 at $59.35 | filing |
| 17 Jul 2026filed 21 Jul 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $2,6591,072 at $2.48 | filing |
| 17 Jul 2026filed 21 Jul 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K324 at $49.97 | filing |
| 17 Jul 2026filed 21 Jul 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K369 at $51.48 | filing |
News
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysELVN · dailypolitical.com · 21 Oct 2026Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Benjamin Hohl; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.